Repligen Corporation
RGENNASDAQHealthcare● Active
$126.06
+$3.75(+3.07%)
Market Cap$7.1B
P/E Ratio—
52W High$175.77
52W Low$100.99
Repligen Corporation (RGEN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RGEN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.74B | $0.63B | $0.63B | $0.80B | $0.67B |
| Cost of Revenue | $0.39B | $0.36B | $0.35B | $0.35B | $0.28B |
| Gross Profit | $0.35B | $0.27B | $0.28B | $0.46B | $0.39B |
| Gross Margin %(computed) | 47.09% | 43.29% | 44.03% | 56.85% | 58.35% |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.04B | $0.04B | $0.04B | $0.03B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.29B | $0.31B | $0.23B | $0.23B | $0.22B |
| Operating Income | $0.06B | ($0.04B) | $0.05B | $0.22B | $0.17B |
| Operating Margin %(computed) | 8.07% | -5.53% | 7.54% | 28.03% | 24.94% |
| Interest Income | $0.03B | $0.00B | $0.00B | $0.01B | $0.00B |
| Interest Expense | $0.02B | $0.02B | $0.01B | $0.00B | $0.01B |
| Income Before Tax | $0.06B | ($0.03B) | $0.06B | $0.22B | $0.15B |
| Income Tax Expense | $0.01B | ($0.00B) | $0.02B | $0.03B | $0.03B |
| Net Income | $0.05B | ($0.03B) | $0.04B | $0.19B | $0.13B |
| Net Margin %(computed) | 6.62% | -4.02% | 5.63% | 23.20% | 19.13% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.87 | $-0.46 | $0.64 | $3.35 | $2.33 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| EBITDA | $0.16B | $0.08B | $0.15B | $0.28B | $0.20B |
| EBITDA Margin %(computed) | 22.26% | 12.65% | 22.98% | 34.60% | 30.31% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Repligen Corporation data
About Repligen Corporation (RGEN) Income Statement
Repligen Corporation (RGEN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RGEN reported revenue of $0.74B, gross profit of $0.35B (gross margin 47.09%), and net income of $0.05B — a net profit margin of 6.62%.
Frequently asked questions
RGEN · 4 questionsRepligen Corporation (RGEN) reported revenue of $0.74B for 2025, up 16.4% year-over-year.
RGEN revenueRGEN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08